305 related articles for article (PubMed ID: 25853389)
21. Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function.
Heideman MR; Wilting RH; Yanover E; Velds A; de Jong J; Kerkhoven RM; Jacobs H; Wessels LF; Dannenberg JH
Blood; 2013 Mar; 121(11):2038-50. PubMed ID: 23327920
[TBL] [Abstract][Full Text] [Related]
22. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
[TBL] [Abstract][Full Text] [Related]
23. Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells.
Kwiecińska P; Wróbel A; Taubøll E; Gregoraszczuk EŁ
Toxicol Lett; 2014 Jan; 224(2):225-32. PubMed ID: 24200999
[TBL] [Abstract][Full Text] [Related]
24. ZEB1 is a Subgroup-Specific Marker of Prognosis and Potential Drug Target in Medulloblastoma.
Fratini L; Dalmolin MGS; Sinigaglia M; da Silveira Perla A; de Farias CB; Brunetto AL; Brunetto AT; da Cunha Jaeger M; Roesler R
Neuromolecular Med; 2023 Mar; 25(1):64-74. PubMed ID: 35716340
[TBL] [Abstract][Full Text] [Related]
25. Valproic acid treatment response in vitro is determined by TP53 status in medulloblastoma.
Mascaro-Cordeiro B; Oliveira ID; Tesser-Gamba F; Pavon LF; Saba-Silva N; Cavalheiro S; Dastoli P; Toledo SRC
Childs Nerv Syst; 2018 Aug; 34(8):1497-1509. PubMed ID: 29785653
[TBL] [Abstract][Full Text] [Related]
26. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer.
Aghdassi A; Sendler M; Guenther A; Mayerle J; Behn CO; Heidecke CD; Friess H; Büchler M; Evert M; Lerch MM; Weiss FU
Gut; 2012 Mar; 61(3):439-48. PubMed ID: 22147512
[TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP.
Bangert A; Cristofanon S; Eckhardt I; Abhari BA; Kolodziej S; Häcker S; Vellanki SH; Lausen J; Debatin KM; Fulda S
Oncogene; 2012 Nov; 31(44):4677-88. PubMed ID: 22266862
[TBL] [Abstract][Full Text] [Related]
28. HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.
Milde T; Lodrini M; Savelyeva L; Korshunov A; Kool M; Brueckner LM; Antunes AS; Oehme I; Pekrun A; Pfister SM; Kulozik AE; Witt O; Deubzer HE
J Neurooncol; 2012 Dec; 110(3):335-48. PubMed ID: 23054560
[TBL] [Abstract][Full Text] [Related]
29. Histone Deacetylase 2 (HDAC2) Inhibitors Containing Boron.
Kavianpour P; Gemmell MCM; Kahlert JU; Rendina LM
Chembiochem; 2020 Oct; 21(19):2786-2791. PubMed ID: 32367603
[TBL] [Abstract][Full Text] [Related]
30. Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects.
Marshall GM; Gherardi S; Xu N; Neiron Z; Trahair T; Scarlett CJ; Chang DK; Liu PY; Jankowski K; Iraci N; Haber M; Norris MD; Keating J; Sekyere E; Jonquieres G; Stossi F; Katzenellenbogen BS; Biankin AV; Perini G; Liu T
Oncogene; 2010 Nov; 29(44):5957-68. PubMed ID: 20697349
[TBL] [Abstract][Full Text] [Related]
31. HDAC1 and HDAC2 collectively regulate intestinal stem cell homeostasis.
Zimberlin CD; Lancini C; Sno R; Rosekrans SL; McLean CM; Vlaming H; van den Brink GR; Bots M; Medema JP; Dannenberg JH
FASEB J; 2015 May; 29(5):2070-80. PubMed ID: 25648995
[TBL] [Abstract][Full Text] [Related]
32. HDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escape.
Conte M; Dell'Aversana C; Benedetti R; Petraglia F; Carissimo A; Petrizzi VB; D'Arco AM; Abbondanza C; Nebbioso A; Altucci L
Oncotarget; 2015 Jan; 6(2):886-901. PubMed ID: 25473896
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological inhibition of LSD1 activity blocks REST-dependent medulloblastoma cell migration.
Callegari K; Maegawa S; Bravo-Alegria J; Gopalakrishnan V
Cell Commun Signal; 2018 Sep; 16(1):60. PubMed ID: 30227871
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines.
Pinkerneil M; Hoffmann MJ; Kohlhof H; Schulz WA; Niegisch G
Target Oncol; 2016 Dec; 11(6):783-798. PubMed ID: 27250763
[TBL] [Abstract][Full Text] [Related]
35. Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma.
Coni S; Mancuso AB; Di Magno L; Sdruscia G; Manni S; Serrao SM; Rotili D; Spiombi E; Bufalieri F; Petroni M; Kusio-Kobialka M; De Smaele E; Ferretti E; Capalbo C; Mai A; Niewiadomski P; Screpanti I; Di Marcotullio L; Canettieri G
Sci Rep; 2017 Mar; 7():44079. PubMed ID: 28276480
[TBL] [Abstract][Full Text] [Related]
36. Autoregulation of the N-myc gene is operative in neuroblastoma and involves histone deacetylase 2.
Kim MK; Carroll WL
Cancer; 2004 Nov; 101(9):2106-15. PubMed ID: 15382088
[TBL] [Abstract][Full Text] [Related]
37. Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro.
Freese K; Seitz T; Dietrich P; Lee SML; Thasler WE; Bosserhoff A; Hellerbrand C
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31635225
[TBL] [Abstract][Full Text] [Related]
38. Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells.
von Bueren AO; Shalaby T; Rajtarova J; Stearns D; Eberhart CG; Helson L; Arcaro A; Grotzer MA
BMC Cancer; 2007 Jan; 7():19. PubMed ID: 17254356
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
40. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]